2 Information about galcanezumab

Marketing authorisation indication

2.1 Galcanezumab (Emgality, Eli Lilly) is 'indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price of galcanezumab is £450.00 per 120‑mg injection (excluding VAT; Monthly Index of Medical Specialities online, accessed October 2020). The company has a commercial arrangement. This makes galcanezumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)